In the development of next-generation antibodies, it may be possible to empower CD137 antibodies with Treg-depleting properties to potentially enhance the efficacy of immunomodulatory therapy for lung cancer and other types of cancer. The gene discussed is TNFRSF9; the disease is lung cancer.